Human Metabolites Should Be Studied Before Phase III Trials, FDA Says
Executive Summary
Manufacturers should conduct toxicity studies of unique and major metabolites and submit the results to FDA before initiating Phase III trials, the agency said in a draft guidance entitled "Safety Testing of Drug Metabolites.